Institution
Tulane University
Education•New Orleans, Louisiana, United States•
About: Tulane University is a education organization based out in New Orleans, Louisiana, United States. It is known for research contribution in the topics: Population & Blood pressure. The organization has 24478 authors who have published 47205 publications receiving 1944993 citations. The organization is also known as: University of Louisiana.
Topics: Population, Blood pressure, Poison control, Receptor, Angiotensin II
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Modeling the ONH as a biomechanical structure generates a group of testable hypotheses regarding the central mechanisms of glaucomatous damage and provides a logic for classifying the principal components of the susceptibility of an individual ONH to a given level of IOP.
976 citations
••
TL;DR: It is proposed that the CL of PMN reflects the generation of singlet oxygen, 1 0 2 , which acts per , se , as the bactericidal and/or CL species.
969 citations
••
Los Angeles Biomedical Research Institute1, University of Münster2, University of California, Los Angeles3, Martin Luther University of Halle-Wittenberg4, Tulane University5, VU University Amsterdam6, Ghent University7, University of Liège8, Bar-Ilan University9, Queen's University10, Saint Louis University11, Université libre de Bruxelles12, University of Manchester13
TL;DR: In this paper, the effects of androgen treatment of hypogonadal men on multiple target organs and the recent studies show short-term beneficial effects of testosterone in older men that are similar to those in younger men.
Abstract: Demographic data clearly demonstrate that the percentage of the population in the older age group is increasing. Androgen deficiency in the aging male has become a topic of increasing interest and debate throughout the world. Cross-sectional and longitudinal data indicate that the testosterone falls progressively with age and that a significant percentage of men over the age of 60 years have serum testosterone levels that are below the lower limits of young adult (age 20–30 years) men (1–4). The principal questions raised by these observations are whether older hypogonadal men will benefit from testosterone treatment and what will be the risks associated with such intervention.
The past decade has brought evidence of benefit of androgen treatment of hypogonadal men on multiple target organs and the recent studies show short-term beneficial effects of testosterone in older men that are similar to those in younger men. This has been comprehensively reviewed and summarized by the Institute of Medicine in ‘Testosterone and Aging: Clinical Research Directions’ (5). Long-term data on the effects of testosterone treatment in the older population are limited mainly to effects on body composition and bone mass (6–11). Key questions of the effects of testosterone on patient reported outcomes and functional benefits that may retard physical or mental frailty of the elderly or improve the quality of life are not yet available. Specific risk data on the prostate and cardiovascular systems are needed.
968 citations
••
Wake Forest University1, Veterans Health Administration2, University of Utah3, Boston University4, Medical University of South Carolina5, Stanford University6, Mayo Clinic7, University of California, San Diego8, Rutgers University9, Tulane University10, National Institutes of Health11, University of Alabama at Birmingham12, Vanderbilt University13, United States Department of Veterans Affairs14, University of Florida15, Medical College of Wisconsin16, Case Western Reserve University17
TL;DR: Among ambulatory adults aged 75 years or older, treating to an SBP target of less than 120 mm Hg compared with an SBp target of more than 140mm Hg resulted in significantly lower rates of fatal and nonfatal major cardiovascular events and death from any cause.
Abstract: Importance The appropriate treatment target for systolic blood pressure (SBP) in older patients with hypertension remains uncertain. Objective To evaluate the effects of intensive ( Design, Setting, and Participants A multicenter, randomized clinical trial of patients aged 75 years or older who participated in the Systolic Blood Pressure Intervention Trial (SPRINT). Recruitment began on October 20, 2010, and follow-up ended on August 20, 2015. Interventions Participants were randomized to an SBP target of less than 120 mm Hg (intensive treatment group, n = 1317) or an SBP target of less than 140 mm Hg (standard treatment group, n = 1319). Main Outcomes and Measures The primary cardiovascular disease outcome was a composite of nonfatal myocardial infarction, acute coronary syndrome not resulting in a myocardial infarction, nonfatal stroke, nonfatal acute decompensated heart failure, and death from cardiovascular causes. All-cause mortality was a secondary outcome. Results Among 2636 participants (mean age, 79.9 years; 37.9% women), 2510 (95.2%) provided complete follow-up data. At a median follow-up of 3.14 years, there was a significantly lower rate of the primary composite outcome (102 events in the intensive treatment group vs 148 events in the standard treatment group; hazard ratio [HR], 0.66 [95% CI, 0.51-0.85]) and all-cause mortality (73 deaths vs 107 deaths, respectively; HR, 0.67 [95% CI, 0.49-0.91]). The overall rate of serious adverse events was not different between treatment groups (48.4% in the intensive treatment group vs 48.3% in the standard treatment group; HR, 0.99 [95% CI, 0.89-1.11]). Absolute rates of hypotension were 2.4% in the intensive treatment group vs 1.4% in the standard treatment group (HR, 1.71 [95% CI, 0.97-3.09]), 3.0% vs 2.4%, respectively, for syncope (HR, 1.23 [95% CI, 0.76-2.00]), 4.0% vs 2.7% for electrolyte abnormalities (HR, 1.51 [95% CI, 0.99-2.33]), 5.5% vs 4.0% for acute kidney injury (HR, 1.41 [95% CI, 0.98-2.04]), and 4.9% vs 5.5% for injurious falls (HR, 0.91 [95% CI, 0.65-1.29]). Conclusions and Relevance Among ambulatory adults aged 75 years or older, treating to an SBP target of less than 120 mm Hg compared with an SBP target of less than 140 mm Hg resulted in significantly lower rates of fatal and nonfatal major cardiovascular events and death from any cause. Trial Registration clinicaltrials.gov Identifier:NCT01206062
966 citations
••
TL;DR: Methods for the isolation, expansion and differentiation of ASCs are presented and described in detail and can be applied to adipose tissues from other species with minimal modifications.
965 citations
Authors
Showing all 24722 results
Name | H-index | Papers | Citations |
---|---|---|---|
Walter C. Willett | 334 | 2399 | 413322 |
JoAnn E. Manson | 270 | 1819 | 258509 |
Frank B. Hu | 250 | 1675 | 253464 |
Eric B. Rimm | 196 | 988 | 147119 |
Krzysztof Matyjaszewski | 169 | 1431 | 128585 |
Nicholas J. White | 161 | 1352 | 104539 |
Tien Yin Wong | 160 | 1880 | 131830 |
Tomas Hökfelt | 158 | 1033 | 95979 |
Thomas E. Starzl | 150 | 1625 | 91704 |
Geoffrey Burnstock | 141 | 1488 | 99525 |
Joseph Sodroski | 138 | 542 | 77070 |
Glenn M. Chertow | 128 | 764 | 82401 |
Darwin J. Prockop | 128 | 576 | 87066 |
Kenneth J. Pienta | 127 | 671 | 64531 |
Charles Taylor | 126 | 741 | 77626 |